When do the patents on TECHNETIUM TC 99M MPI MDP expire, and when will generic TECHNETIUM TC 99M MPI MDP be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	TECHNETIUM TC 99M MPI MDP	technetium tc-99m medronate kit	INJECTABLE;INJECTION	018141-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ge Healthcare	TECHNETIUM TC 99M MPI MDP	technetium tc-99m medronate kit	INJECTABLE;INJECTION	018141-002	Jun 12, 1989		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Technetium Tc 99m MPI MDP is a technetium-99m medronate radiopharmaceutical used primarily for skeletal imaging. Its investment profile is driven by nuclear-medicine infrastructure, isotope supply, hospital utilization, reimbursement and manufacturing reliability rather than by patent exclusivity. The product has limited strategic value as a standalone branded medicine but can support a broader radiopharmaceutical portfolio with recurring hospital demand and operational barriers to entry.

What is Technetium Tc 99m MPI MDP?

Technetium Tc 99m MPI MDP is an injectable diagnostic radiopharmaceutical containing technetium-99m labeled medronate, also called methylene diphosphonate or MDP.

Attribute	Assessment
Active diagnostic agent	Technetium Tc 99m medronate
Common abbreviation	Tc-99m MDP
Primary use	Bone scintigraphy and skeletal imaging
Therapeutic category	Diagnostic radiopharmaceutical
Administration	Intravenous injection
Manufacturer reference	MPI commonly refers to Mallinckrodt Pharmaceuticals, a major nuclear-medicine supplier
Patient setting	Hospitals, imaging centers and nuclear pharmacies
Commercial form	Ready-to-use injection or kit-based preparation, depending on product
Revenue model	Per-dose radiopharmaceutical sales, hospital contracts and nuclear-pharmacy distribution
Patent dependence	Low
Supply-chain dependence	High

The product localizes in areas of increased osteogenic activity and is used to evaluate bone lesions, fractures, infection, metastatic disease and other skeletal abnormalities. The FDA label identifies skeletal imaging as the principal clinical application.[1]

Technetium-99m has a physical half-life of approximately six hours. The short half-life limits inventory duration and requires coordinated production, radiolabeling, quality control and delivery. Those requirements create operational barriers even when patent barriers are limited.

What is the FDA regulatory status of Technetium Tc 99m MPI MDP?

Technetium Tc 99m medronate is an FDA-approved diagnostic radiopharmaceutical. The product is administered by trained nuclear-medicine personnel under applicable radioactive-material handling and medical-use requirements.

The FDA-approved labeling covers preparation, intravenous administration, skeletal imaging and radiation-safety information.[1] The product does not require the therapeutic clinical evidence associated with an oncology or chronic-care drug because it is used as a diagnostic imaging agent.

What FDA pathway applies?

The regulatory pathway depends on the commercial presentation:

A ready-to-use approved injection is regulated under an approved drug application.
A cold kit containing medronate and other formulation components requires radiolabeling with sodium pertechnetate Tc-99m before administration.
Compounded or pharmacy-prepared radiopharmaceuticals may fall under hospital and nuclear-pharmacy compounding requirements, including applicable provisions of Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

The most important regulatory risks are manufacturing compliance, sterility, radionuclide handling, dose calibration, labeling and batch-release controls. Clinical differentiation is limited.

What patents protect Technetium Tc 99m MPI MDP?

The product has no evident active composition-of-matter patent moat comparable to patented specialty pharmaceuticals. Medronate and technetium-based bone imaging have been used clinically for decades, and the core technology is mature.

Patent category	Investment significance
Composition patent on medronate	No meaningful current exclusivity expected
Composition patent on Tc-99m MDP	No practical modern patent moat
Use patent for bone imaging	Limited value because the use is established and broad
Formulation patent	Potentially relevant for stability, kit composition or preparation
Manufacturing patent	May protect process efficiency but rarely blocks substitution
Device or delivery patent	Usually immaterial for standard intravenous administration
Trade secrets	Potential value in radiolabeling, logistics and quality systems

The principal intellectual-property exposure is likely to arise from narrow formulation, kit, manufacturing or packaging claims rather than from the active diagnostic agent. Patent value is therefore subordinate to manufacturing capacity, regulatory approvals and distribution coverage.

Does Technetium Tc 99m MPI MDP have Orange Book protection?

The product may appear in FDA drug databases under an approved application or related radiopharmaceutical listing, but Orange Book listing does not create exclusivity by itself. Orange Book protection depends on active patent information submitted by the applicant and accepted for listing by FDA.[2]

For Tc-99m MDP, commercial competition is generally determined by approved products, hospital purchasing contracts and pharmacy preparation capabilities rather than by Paragraph IV patent litigation. The absence of a major patent estate materially reduces the probability of a conventional patent-driven launch blockade.

When does Technetium Tc 99m MPI MDP lose exclusivity?

The core product has effectively passed its ordinary market-exclusivity period. The commercial market is mature and contains multiple sources of technetium-based diagnostic products and related bone-imaging agents.

Exclusivity type	Expected status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the general bone-imaging indication
Pediatric exclusivity	Not a current commercial barrier
New indication exclusivity	Limited relevance
Composition patent exclusivity	Expired or commercially immaterial
Formulation exclusivity	Potentially narrow and product-specific
Manufacturing exclusivity	Contractual or operational, not market-wide

The practical generic-entry question is therefore not when a patent expires. It is whether a competing supplier can obtain approval, secure technetium supply, meet radiopharmaceutical quality standards and deliver doses within the relevant geographic window.

How many patents cover Technetium Tc 99m MPI MDP?

No meaningful portfolio of active, broad patents is required to commercialize the underlying diagnostic concept. The relevant patent universe can include:

Historical patents covering diphosphonate compounds.
Earlier patents covering technetium complexing chemistry.
Kit formulations and stabilizer systems.
Radiolabeling processes.
Packaging, dose-calibration or distribution systems.
Narrow patents covering specific imaging combinations or workflow technologies.

Most historical patents do not create a current exclusionary position because patent terms have expired. A patent search for a particular supplier must distinguish expired foundational patents from live claims that cover a specific kit, process or delivery configuration.

What formulations are protected by Technetium Tc 99m MDP products?

Formulation economics are more important than formulation exclusivity. A typical product must support:

Stable complex formation between medronate and technetium-99m.
Sterile intravenous administration.
Acceptable pH and isotonicity.
Low endotoxin levels.
Reliable radiochemical purity.
Usable shelf life before radiolabeling.
Consistent performance across technetium eluate sources.

Cold-kit products can reduce distribution complexity because the kit is shipped before radioactive labeling. Ready-to-use products reduce preparation work for hospitals and nuclear pharmacies but require tighter radioactive logistics.

A formulation patent may have value if it materially extends kit shelf life, improves radiochemical purity or reduces preparation failures. Such a patent would usually protect a narrow commercial process rather than the entire Tc-99m MDP market.

What generic entry risks exist for Technetium Tc 99m MPI MDP?

Generic-entry risk is high in principle because the active diagnostic technology is mature and clinically substitutable. The practical rate of entry is constrained by operating requirements.

Main entry barriers

Barrier	Effect on new entrants
Access to Tc-99m	Requires reliable molybdenum-99 and generator or reactor supply
Short half-life	Prevents conventional long-term inventory
Nuclear pharmacy network	Requires local or regional distribution capability
Sterile manufacturing	Raises compliance and capital requirements
Dose calibration	Requires specialized equipment and validated procedures
Hospital contracting	Favors established suppliers
Radiation licensing	Adds facility and personnel requirements
Low unit price	Limits return on incremental manufacturing investment

A new entrant can receive regulatory approval but still fail to obtain adequate commercial scale. Product availability, order cutoffs, delivery radius and replacement-dose capability can matter more than the nominal list price.

Which companies compete with MPI MDP products?

The relevant competitive set includes established radiopharmaceutical manufacturers, nuclear pharmacies and hospital-based compounding operations. Major industry participants have included:

Mallinckrodt Pharmaceuticals.
Cardinal Health.
Curium.
Jubilant Radiopharma.
Lantheus Holdings, in selected nuclear-medicine categories.
Regional radiopharmacies and health-system nuclear pharmacies.

Competition is often regional rather than purely national. A supplier with production facilities near hospitals can compete effectively against a larger company with weaker local delivery coverage.

How does Tc-99m MDP compare with competing bone-imaging products?

Product category	Primary imaging role	Commercial comparison
Tc-99m MDP	Conventional bone scintigraphy	Mature, low differentiation, broad availability
Tc-99m HDP	Bone scintigraphy	Clinically similar use; competes on supply and contracting
Tc-99m DPD	Bone imaging in selected markets	Geographic and regulatory availability varies
F-18 sodium fluoride	PET bone imaging	Higher image quality and resolution but higher infrastructure requirements
Ga-68 or F-18 targeted agents	Indication-specific imaging	More differentiated, often higher strategic value

The main competitive threat is not a patented substitute. It is imaging migration toward PET-based methods where installed equipment, reimbursement and clinical workflow support adoption. Conventional Tc-99m bone scans remain relevant because SPECT and planar imaging are widely available and generally lower cost.

What is the commercial outlook and revenue exposure?

Tc-99m MDP is a recurring-use diagnostic product with relatively predictable clinical demand. Revenue is tied to procedure volume rather than long-term treatment duration.

Positive commercial factors

Large installed base of gamma cameras and SPECT systems.
Established physician familiarity.
Broad use in oncology, orthopedics and emergency imaging.
Repeat hospital and nuclear-pharmacy demand.
Low clinical switching costs between equivalent suppliers.
Limited dependence on consumer marketing.

Negative commercial factors

Low differentiation and pricing pressure.
Radioactive decay creates product waste.
Revenue can be affected by isotope shortages.
PET adoption can reduce conventional bone-scan volume.
Hospital purchasing groups exert price pressure.
A manufacturing interruption can rapidly affect sales.

The product is most valuable as part of a radiopharmaceutical platform. A supplier can use an MDP product to maintain nuclear-pharmacy relationships and route density, while selling higher-margin PET agents, cardiac products or oncology radiopharmaceuticals through the same network.

What manufacturing and supply-chain risks affect Tc-99m MDP?

The supply chain begins with molybdenum-99 production, continues through technetium-99m generator availability or institutional supply, and ends with radiolabeling, quality control and delivery.

Key supply risks

Reactor outages or molybdenum-99 shortages.
Generator delivery delays.
Regional transport restrictions.
Radiopharmaceutical production failures.
Sterility or quality deviations.
Hospital order volatility.
Weather-related delivery disruption.
Reduced utilization caused by imaging-center closures or capital constraints.

The short half-life of Tc-99m prevents manufacturers from using ordinary pharmaceutical inventory strategies. A supply failure can produce same-day or next-day clinical disruption. This makes redundancy, local production and logistics coverage central investment variables.

What patent litigation affects Technetium Tc 99m MPI MDP?

Tc-99m MDP is not associated with the type of recurring high-value patent litigation seen in branded oncology, immunology or diabetes products. Paragraph IV challenges are unlikely to be the primary market event because the core technology is old and the product is commercially substitutable.

Potential disputes are more likely to involve:

Manufacturing processes.
Kit formulation claims.
Regulatory exclusivity for a specific presentation.
Distribution contracts.
Hospital purchasing arrangements.
Compounding or pharmacy-scope issues.
Supply agreements involving isotope generators or nuclear pharmacies.

Litigation risk is therefore operational and commercial rather than centered on a single blocking patent.

Are biosimilars relevant to Technetium Tc 99m MPI MDP?

No. Tc-99m MDP is a small-molecule radiopharmaceutical, not a biologic. Biosimilar regulation does not apply. Competitive entry occurs through approved drug products, radiopharmacy preparation and hospital procurement rather than through the abbreviated biologics pathway.

What licensing deals affect the product?

Licensing value is limited for the mature MDP product itself. The more relevant transactions involve:

Regional distribution rights.
Nuclear-pharmacy service agreements.
Isotope generator supply.
Contract manufacturing.
Hospital-system purchasing contracts.
Portfolio acquisitions involving radiopharmaceutical assets.

A standalone license for Tc-99m MDP would generally have less strategic value than a transaction that combines the product with generator access, radiopharmacy capacity or a differentiated PET portfolio.

What generic launch scenarios are plausible?

Scenario 1: Stable mature market

Existing suppliers maintain broad availability. Price competition remains moderate, and demand tracks conventional bone-imaging volume. This is the most likely base case.

Scenario 2: Supplier consolidation

A manufacturer exits or reduces production. Remaining suppliers gain temporary pricing power, but hospitals seek alternative approved sources and local radiopharmacies expand capacity.

Scenario 3: PET substitution

F-18 sodium fluoride and disease-specific PET tracers gain use in oncology and complex bone disease. Tc-99m MDP volume declines gradually, while demand remains in lower-cost, high-throughput and resource-constrained settings.

Scenario 4: Isotope disruption

Molybdenum-99 or generator shortages reduce available Tc-99m doses. The impact is immediate because radioactive inventory cannot be stockpiled for long periods. Suppliers with diversified isotope access and redundant production sites have the strongest position.

How strong is the patent estate for Technetium Tc 99m MPI MDP?

The patent estate is weak as a standalone investment thesis. Product defensibility comes from:

FDA-approved manufacturing.
Licensed radioactive-material facilities.
Nuclear-pharmacy density.
Hospital contracts.
Reliable isotope procurement.
Quality systems.
Delivery performance.
Portfolio bundling.

An investor should value the product as a cash-flow and platform asset rather than as a patent-protected growth product. The strongest commercial position belongs to suppliers that combine Tc-99m MDP with higher-margin radiopharmaceuticals and maintain reliable regional distribution.

What is the investment thesis for Technetium Tc 99m MPI MDP?

The investment case is defensive and infrastructure-based.

Investment factor	Assessment
Demand durability	Moderate to strong
Pricing power	Low to moderate
Patent protection	Weak
Regulatory barrier	Moderate
Manufacturing barrier	High
Supply-chain risk	High
Margin expansion	Limited as a standalone product
Platform value	Potentially meaningful
Litigation exposure	Low relative to patented specialty drugs
Growth potential	Low for the product; higher within a broader radiopharmaceutical portfolio

The product is attractive when acquired at a valuation based on stable utilization, reliable supply and cross-selling potential. It is less attractive when valued as a high-growth branded medicine or patent-protected asset.

Key Takeaways

Technetium Tc 99m MPI MDP is a mature diagnostic radiopharmaceutical used primarily for bone imaging.
Its core active technology has little meaningful patent exclusivity.
FDA status, sterile manufacturing and radioactive-material controls create the main barriers to entry.
Generic competition is structurally high, but operational execution limits the number of reliable suppliers.
The largest commercial risks are isotope shortages, production failures and migration toward PET imaging.
The product has greater value as part of a radiopharmaceutical and nuclear-pharmacy platform than as a standalone growth asset.
Patent litigation and Paragraph IV challenges are unlikely to define the market.
Revenue is recurring but exposed to hospital procedure volumes, reimbursement and regional delivery economics.

FAQs About Technetium Tc 99m MPI MDP

Is Technetium Tc 99m MDP the same as Technetium Tc 99m HDP?

No. Both are technetium-labeled diphosphonate agents used for skeletal imaging, but they contain different diphosphonate ligands. They can compete clinically in overlapping applications.

Is Technetium Tc 99m MDP a generic drug?

It is a mature multisource radiopharmaceutical product. The relevant competitive structure is closer to a generic diagnostic market than to a protected branded-drug market.

Can hospitals compound Technetium Tc 99m MDP?

Nuclear pharmacies and authorized facilities can prepare or radiolabel certain products under applicable FDA, state and radioactive-material requirements. The legal pathway depends on the product presentation and facility status.

Does F-18 sodium fluoride replace Tc-99m MDP?

It can replace Tc-99m MDP in selected bone-imaging workflows, particularly where PET infrastructure and reimbursement are available. It does not eliminate Tc-99m MDP demand across the broader hospital market.

What would increase the value of an MDP radiopharmaceutical business?

The strongest value drivers are reliable isotope access, high nuclear-pharmacy route density, multi-product hospital contracts, low production failure rates and cross-selling into higher-margin PET or therapeutic radiopharmaceuticals.

References

U.S. Food and Drug Administration. (n.d.). Technetium Tc 99m medronate injection prescribing information. FDA drug labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
U.S. Food and Drug Administration. (2023). Compounding and radiopharmaceutical regulatory information. https://www.fda.gov/drugs/human-drug-compounding
International Atomic Energy Agency. (2022). Technetium-99m radiopharmaceuticals and molybdenum-99 supply. https://www.iaea.org/topics/medical-radioisotopes
Society of Nuclear Medicine and Molecular Imaging. (n.d.). Bone scintigraphy and technetium-99m diphosphonate imaging. https://snmmi.org/Practice-Policy/Practice-Guidelines/Practice-Guidelines-Home

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for TECHNETIUM TC 99M MPI MDP